Literature DB >> 34322937

Traditional medicines prescribed for prevention of COVID-19: Use with caution.

Rajeevalochana Parthasarathy1, Milly Mathew1, Priyanka Koshy2, Madhusri Babu1, Georgi Abraham1.   

Abstract

Acute interstitial nephritis can result due to exposure to any medication, toxins, infections or malignancy. In the midst of this Coronavirus (COVID-19) pandemic, there has been a race for finding remedies to prevent the spread of and control the complications due to Severe Acute Respiratory Syndrome Coronavirus 2. Certain Indian medicinal herb concoctions like kabasura kudineer and nilavembu kudineer are being widely publicized to boost immunity and reduce the risk of developing COVID-19. Little knowledge exists about the adverse effects of these herbal remedies. We report two patients who presented to us with vague complaints following the ingestion of kabasura kudineer and we diagnosed them with acute tubulointerstitial nephritis (ATIN). The temporal relationship of ingestion of these remedies to the development of ATIN calls for vigilance and caution with regular monitoring of renal functions especially in those with chronic kidney disease.
© 2021 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  COVID-19; acute kidney injury (AKI); herbal medications

Mesh:

Substances:

Year:  2021        PMID: 34322937      PMCID: PMC8420558          DOI: 10.1111/nep.13947

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.358


INTRODUCTION

The COVID‐19 pandemic, which first reported in Wuhan, China, has now more than 10 million people infected worldwide. Various therapeutic strategies are being researched, and trials are being done to find the prevention and cure for this deadly virus. Traditional Indian systems of medications which include Siddha have also offered a variety of herbs to improve immunity to prevent the development of COVID‐19. Official Siddha formulations kabasura kudineer chooranam is believed to be a potent formulation with anti‐viral and immuno‐modulatory properties. , We report two patients who developed acute kidney injury (AKI) following the consumption of this formulation.

CASE HISTORY

Patient K

Mr K, a 51‐year‐old male who had an aortic valve replacement in 2013 presented with loss of appetite and easy fatigability of 1‐week duration. He reported no history of diabetes or hypertension. His medications included warfarin and nebivolol. He had no fever, rash, joint pains, cough, or hemoptysis. He had not consumed any known nephrotoxic agents like antibiotics, non‐steroidal anti‐inflammatory drugs or proton pump inhibitors (PPI). On further questioning, he said that he was taking 'kabasura kudineer' 60 ml once a day a week prior to the start of his symptoms. His baseline serum creatinine (SCr) done 2 months prior was 1.1 mg/dl. At presentation, he was euvolemic and had a blood pressure of 120/70 mmHg. His urinalysis showed no proteinuria but sediment revealed 3–5 WBC/HPF, 10–15 RBC/HPF and many granular casts. Mid‐stream urine culture was sterile. Serum creatinine at presentation was 2.8 mg/dl and international normalized ratio was 2.4. Ultrasound showed normal sized kidneys with no hydronephrosis. After stopping warfarin and the herbal drink for 5 days, a kidney biopsy was performed as serum creatinine was still 2.8 mg/dl. Renal biopsy revealed acute tubulointerstitial nephritis (ATIN) in the background of mild arteriosclerosis, immunofluorescence (IF) was negative (Figure 1A). He was started on 0.5 mg/kg/day of prednisone. SCr after 2 weeks is 1.3 mg/dl and steroids were tapered by 5 mg every 5 days. Three months later his SCr remains at 1.2 mg/dl.
FIGURE 1

(A) Interstitial inflammation with tubular injury and WBC cast (H&E). (B) Tubular injury with neutrophilc tubulitis and WBC cast; interstitial edema and inflammation (H&E)

(A) Interstitial inflammation with tubular injury and WBC cast (H&E). (B) Tubular injury with neutrophilc tubulitis and WBC cast; interstitial edema and inflammation (H&E)

Patient D

Mr D, a 63‐year‐old male with no known co‐morbidities presented with nausea of 1‐week duration. He was on no medications except for kabasura kudineer around 30–40 ml twice a day for 2 days prior to the symptoms. He had not consumed any known nephrotoxic agents like antibiotics, NSAID or PPI. At presentation he was anaemic, euvolemic and had a blood pressure of 140/70 mmHg. He was afebrile with no rash or joint swelling. He did not have any baseline blood tests done prior to this episode. SCr was 3.8 mg/dl, haemoglobin 7.2 g/dl and urinalysis showed many WBC and WBC casts. Mid‐stream urine culture was negative and ultrasound showed normal sized kidneys. Renal biopsy was performed which showed ATIN on a background of early IgA staining on IF (Figure 1B). He was started on 0.5 mg/kg/day of prednisone after confirming a normal gastroscopy. The serum SCr decreased to 2.8 mg/dl a week later. He was tapered off the steroids over 6 weeks and his serum creatinine after 2 months is 1.1 mg/dl. The details of the both the patients are illustrated in Table 1.
TABLE 1

Clinical characteristics of the patients

NameMr. KMr. D
Age51 years63 years
GenderMaleMale
Base line serum creatinine [SCr (mg/dl)]1.21 mg/dl in January 2020Not available
Diabetes mellitusNoNo
Systemic hypertensionNoNo
OthersS/P. Aortic valve replacement (January/2013)None
MedicationsWarfarin and metoprololNone
Urine routineAlbumin‐nil, sugar‐nil, pus cells 3–5, epithelial cells 1–2, RBC 10–15, granular cast presentAlbumin‐nil, sugar‐nil, Pus cells >50, epithelial cells 2–3, RBC 3–5, WBC cast and granular cast present
Haemoglobin (g/dl)12.97.2
Total leucocyte count (cells/mm3)18 3008900
Platelet (Lak/mm3)3.003.18
Urea (mg/dl)2974
SCr at presentation (mg/dl)3.563.25
Sodium (mmol/L)138124
Potassium (mmol/L)3.472.89
Bicarbonate (mmol/L)2930
Calcium (mg/dl)8.68.4
Phosphorous (mg/dl)3.24.4
T. protein (g/dl)10.36.5
Albumin (g/dl)4.73.4
TSH (mIU/L)3.221.95
HbA1c (%)5.6 (23 December 2019)6.3

Oro pharyngeal

Swab for RT‐PCR COVID

NegativeNegative
Kidney biopsy Findings

Acute tubulointerstitial nephritis

Mild to moderate

Arteriosclerosis

Interstitial fibrosis and tubular atrophy 10%–15%

Acute tubulointerstitial nephritis

IgA nephropathy

Interstitial fibrosis and tubular atrophy 5%–10%

ImmunofluorescenceNegative for IgA, IgG, C3, Kappa and LambdaIgA (2+), C3 (Trace), Lambda (2+) and Kappa (Trace)
Treatment givenPrednisone 0.5 mg/kg bodyweight/day tapered over 8 weeksPrednisone 0.5 mg/kg bodyweight/day tapered over 6 weeks
SCr (mg/dl) after 2 weeks of treatment with steroids1.492.23
SCr (mg/dl) on further follow up1.2 mg/dl after 3 months1.1 mg/dl after 2 months
Side effects of treatmentHyperglycemia needing medicationsHyperglycemia needing medications
Clinical characteristics of the patients Oro pharyngeal Swab for RT‐PCR COVID Acute tubulointerstitial nephritis Mild to moderate Arteriosclerosis Interstitial fibrosis and tubular atrophy 10%–15% Acute tubulointerstitial nephritis IgA nephropathy Interstitial fibrosis and tubular atrophy 5%–10%

DISCUSSION

Acute kidney injury with ATIN can occur due to numerous prescribed and over‐the‐counter medications and health drinks. It is estimated that one in three cases of ATIN can be due to endogenous and exogenous toxins. Establishing the causality of health food & health drink toxins inducing kidney disease is a challenge and requires a detailed history, time course, assessment of competing risk factors, and mechanism of injury and biological plausibility of the toxins. Kidney toxicity of the agent and underlying patient characteristics such as increasing age, alter the metabolism and pathway of excretion of various agents administered and enhance the risk of the development of ATIN. The National Kidney Foundation has cautioned against the use of herbal supplements and drugs without adequate monitoring as vulnerable populations like those with chronic kidney disease (CKD) can suffer significant damage. , The kidneys which are involved in the elimination of xenobiotics, environmental agent and metals through glomerular filtration, tubular secretion and metabolism is highly vulnerable to the toxicity of these agents. Siddha system of medicine, one of the oldest systems of medicine, has been promoting 'kabasura kudineer', as a formulation for immunity building affecting tumour necrosis factor signalling pathways. It contains 16 constituents (Zingiber officinale, Piper longum, Syzygium aromaticum, Cirucirukancori ver, Tragia involucrata, Anacyclus pyrethrum, Solanum anguivi, Terminalia chebula, Justicia adhatoda, Coleus aromaticus, Saussurea costus, Tinospora cordifolia, Clerodendron serratum, Andrographis paniculata, Cissampelos pareira, Cyperus rotundus and neer [water]). It has been recommended to mix 8 g of the powder in four glasses of water and boil to reduce it to a glass and to be taken two to three times a day. Active phytoconstituents of this polyherbal decoction is supposed to have high affinity to the spike protein of the COVID‐19 virus and hence prevents its binding to the ACE2 receptor on the host cell. , Among the constituents, Syzygium aromaticum, Solanum anguivi, Andrographis paniculata and Cyperus rotundus have been known to produce various degrees of nephrotoxicity according to case reports and series. To the best of our knowledge, ATIN due to 'kabasura kudineer' has not yet been reported. We referred to the criteria by Naranjo et al. to report an adverse drug event. A score of 6 was derived using these criteria, rating this adverse reaction as “probable”. Nephrotoxicity was attributed to this drug on the basis of the criteria of Naranjo et al., clinical onset of AKI, absence of any other nephrotoxic drugs being administered, and histopathological findings on the renal biopsy. In our two patients, the temporal relationship to kidney injury with no previous known nephrotoxic agents establishes a cause and effect relationship. The ATIN seems to be dose independent as both the patients took different amounts of the drug and the time period to the development of AKI has also been variable. Interestingly both had gastrointestinal symptoms after taking the formulation. It is worthwhile to think both these patients had some baseline CKD (as evidenced on biopsy) which makes them more vulnerable to AKI. Patient D had mesangial IgA deposits in the kidney which may be mean he had pre‐existing IgA nephropathy (IgAN) or it was an incidental IgA deposition. However, the kidney biopsy findings in patient D were not suggestive of IgAN. Both patients improved after stopping the formulation and with the addition of a short course of low dose steroids. A multi‐pronged approach for prevention includes increased awareness for both providers and patients of the potential nephrotoxicity of herbal formulations. A high index of suspicion of potential toxicity is necessary for early recognition and management.
  10 in total

Review 1.  Toxicity of Herbs, Vitamins, and Supplements.

Authors:  Elliot Charen; Nikolas Harbord
Journal:  Adv Chronic Kidney Dis       Date:  2020-01       Impact factor: 3.620

2.  Deaths: Leading Causes for 2017.

Authors:  Melonie Heron
Journal:  Natl Vital Stat Rep       Date:  2019-06

3.  Clove oil ingestion in an infant.

Authors:  B W Lane; M J Ellenhorn; T V Hulbert; M McCarron
Journal:  Hum Exp Toxicol       Date:  1991-07       Impact factor: 2.903

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 5.  Drug-induced kidney diseases.

Authors:  N P Singh; A Ganguli; A Prakash
Journal:  J Assoc Physicians India       Date:  2003-10

6.  Andrographolide induced acute kidney injury: analysis of 26 cases reported in Chinese Literature.

Authors:  Wu-Xing Zhang; Zhi-Min Zhang; Zhi-Qiang Zhang; Yang Wang; Wei Zhou
Journal:  Nephrology (Carlton)       Date:  2014-01       Impact factor: 2.506

Review 7.  COVID-19: A promising cure for the global panic.

Authors:  Balachandar Vellingiri; Kaavya Jayaramayya; Mahalaxmi Iyer; Arul Narayanasamy; Vivekanandhan Govindasamy; Bupesh Giridharan; Singaravelu Ganesan; Anila Venugopal; Dhivya Venkatesan; Harsha Ganesan; Kamarajan Rajagopalan; Pattanathu K S M Rahman; Ssang-Goo Cho; Nachimuthu Senthil Kumar; Mohana Devi Subramaniam
Journal:  Sci Total Environ       Date:  2020-04-04       Impact factor: 7.963

8.  Acute interstitial nephritis induced by Solanum nigrum.

Authors:  Sung Sik Oh; Myung Woo Choi; Mi Rim Choi; Jong Hwa Lee; Hyun Ju Yang; Yeong Jin Choi; A Young Cho; Kwang Young Lee; In O Sun
Journal:  Kidney Res Clin Pract       Date:  2016-05-18

9.  Traditional medicines prescribed for prevention of COVID-19: Use with caution.

Authors:  Rajeevalochana Parthasarathy; Milly Mathew; Priyanka Koshy; Madhusri Babu; Georgi Abraham
Journal:  Nephrology (Carlton)       Date:  2021-07-28       Impact factor: 2.358

10.  In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.

Authors:  Gangarapu Kiran; L Karthik; M S Shree Devi; P Sathiyarajeswaran; K Kanakavalli; K M Kumar; D Ramesh Kumar
Journal:  J Ayurveda Integr Med       Date:  2020-05-25
  10 in total
  3 in total

1.  Have we missed AINything? Acute interstitial nephritis in SARS-CoV-2 infection and vaccination.

Authors:  Joshua Storrar; Satoru Kudose; Alexander Woywodt
Journal:  Clin Kidney J       Date:  2022-05-24

2.  Correlation of AKI with Risk Factors, Ventilatory Support, Renal Replacement Therapy in a Cohort of COVID-19 Patients.

Authors:  Phanidhar Mogga; Shreevidya Venkatraman; Urjitha Rajagopalan; Prashanth Rajagopalan; Prabhu Radhan; Kumaresan Maithrayie; Sivaraj Padmanabhan; Swamikannu Murugan; Archana Nagarajan; Chandrasekaran Venkataraman; Milly Mathew; Georgi Abraham; Nancy Lesley
Journal:  Indian J Nephrol       Date:  2022-07-12

3.  Traditional medicines prescribed for prevention of COVID-19: Use with caution.

Authors:  Rajeevalochana Parthasarathy; Milly Mathew; Priyanka Koshy; Madhusri Babu; Georgi Abraham
Journal:  Nephrology (Carlton)       Date:  2021-07-28       Impact factor: 2.358

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.